Abstract: Techniques for gesture-based device connections are described. For example, a method may comprise receiving video data corresponding to motion of a first computing device, receiving sensor data corresponding to motion of the first computing device, comparing, by a processor, the video data and the sensor data to one or more gesture models, and initiating establishment of a wireless connection between the first computing device and a second computing device if the video data and sensor data correspond to gesture models for the same gesture. Other embodiments are described and claimed.

Abstract: Techniques for gesture-based device connections are described. For example, a method may comprise receiving video data corresponding to motion of a first computing device, receiving sensor data corresponding to motion of the first computing device, comparing, by a processor, the video data and the sensor data to one or more gesture models, and initiating establishment of a wireless connection between the first computing device and a second computing device if the video data and sensor data correspond to gesture models for the same gesture. Other embodiments are described and claimed.

Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: This application relates to apparatus and methods for identifying anomalies within a time series. In some examples, a computing device receives sales data identifying a sale of at least one item, and aggregates the received data in a database. The computing device may generate a plurality of time series based on the aggregated sales data. The computing device may extract features from the plurality of time series, and generate an alerting algorithm that is based on clusters of the extracted features. The computing device may apply the alerting algorithm to a time series generated from received sales data to determine whether the time series is an anomaly. Based on the determination, the computing device may generate and transmit anomaly data identifying whether the time series is an anomaly, such as to another computing device.

Abstract: A method and system for identifying and labeling fraudulent store return activities includes receiving, by a server, retailer events from an online transaction system of a retailer, the retailer events comprising records of transactions between customers and the retailer, including sale, exchange and return activities across multiple stores. The retailer events are processed to build a network that associates stores, transactions, payment instruments, and customer identification over related activity sequences of transactions.

Abstract: The present disclosure provides methods and systems for identifying natural product-encoding multi-gene clusters (MGCs). In some embodiments, the present disclosure also teaches methods for producing sequenced and assembled metagenomic libraries that are amenable to MGC search bionformatic tools and techniques.

Abstract: This application relates to apparatus and methods for identifying anomalies within a time series. In some examples, a computing device receives sales data identifying a sale of at least one item, and aggregates the received data in a database. The computing device may generate a plurality of time series based on the aggregated sales data. The computing device may extract features from the plurality of time series, and generate an alerting algorithm that is based on clusters of the extracted features. The computing device may apply the alerting algorithm to a time series generated from received sales data to determine whether the time series is an anomaly. Based on the determination, the computing device may generate and transmit anomaly data identifying whether the time series is an anomaly, such as to another computing device.

Abstract: The present disclosure provides methods and systems for identifying natural product-encoding multi-gene clusters (MGCs). In some embodiments, the present disclosure also teaches methods for producing sequenced and assembled metagenomic libraries that are amenable to MGC search bionformatic tools and techniques.

Abstract: The present disclosure provides methods and systems for identifying natural product-encoding multi-gene clusters (MGCs). In some embodiments, the present disclosure also teaches methods for producing sequenced and assembled metagenomic libraries that are amenable to MGC search bionformatic tools and techniques.

Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.

Abstract: Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.

Abstract: Two-part cyanoacrylate/cationically curable adhesive systems are provided.

Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

Abstract: Polymer blends, methods of making the polymer blends, and articles of manufacture that include the polymer blends are described. A polymer blend can include a high density polyethylene (HDPE) polymer and a random block copolymer. The random block copolymer can include two different saturated alkane blocks between aromatic blocks (e.g., two styrenic blocks).

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: The present invention relates to a process for the production of an ethylene-propylene-diene terpolymer (EPDM) composition in a reaction vessel comprising the following steps in this order: (a) supplying a quantity of a first composition comprising an ethylene copolymer or a propylene copolymer and a first peroxide to the reaction vessel; (b) supplying a quantity of a second composition comprising EPDM and a second peroxide to the reaction vessel; or (a) supplying a quantity of a second composition comprising EPDM and a second peroxide to the reaction vessel; (b) supplying a quantity of a first composition comprising an ethylene copolymer or a propylene copolymer and a first peroxide to the reaction vessel; and (c) exposing the contents of the reaction vessel under stirring to a temperature of 100-200° C.

Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

Abstract: An Artificial Intelligence (AI) based resource identification system enables identifying available resources in response to receiving a request for resources. The request attributes are mapped to the attributes of the resources in a resource pool. Matching index scores are calculated and resources that match the request can be selected based on the matching index scores. If no resources are available suitable alternate resources with lower matching index scores are suggested so that a user has the choice to filter this alternate resources based on a threshold score. Particular suggestions to change one or more of the request attributes can be provided based on analysis of the mapping of the request and the resource attributes which enables the resource identification system to suggest changes to one or more of the skill attributes, level attributes, time attributes or location attributes of the request.